NGNE (Neurogene) Short Percentage of Float


NGNE Neurogene Inc NGNE
12 GF Score
Price $32.05
! 4 Warning Signs
View Full Analysis

What is Neurogene Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

NGNE vs SGMT, IPSC, UPB: Short Percentage of Float Comparison

For the Biotechnology subindustry, Neurogene's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neurogene Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neurogene's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Neurogene's Short Percentage of Float falls into.


NGNE
12GF Score
Neurogene Inc NGNE
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neurogene Business Description

Other Exchanges UU8:Germany
Address 535 W 24th Street, 5th Floor, New York, NY, USA, 10011
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
12GF Score

Get the complete analysis for NGNE

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$32.05
Price